PreprintCited by 478Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Research Studies

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Open access

Politi, Katerina, Zakowski, Maureen F., Fan, Pang-Dian, Schonfeld, Emily A., Pao, William, Varmus, Harold E.·2006·Genes & Development

DOI 10.1101/gad.1417406

Open this paper in CoChat — free account Open PDF

Abstract

Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor ( EGFR ) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Nearly 90% of the EGFR mutations are either short, in-frame deletions in exon 19 or point mutations that result in substitution of arginine for leucine at amino acid 858 (L858R). To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant ( EGFR Δ L747–S752 ) or the L858R mutant ( EGFR L858R ) in type II pneumocytes under the control of doxycycline. Expression of either EGFR mutant leads to the development of lung adenocarcinomas. Two weeks after induction with doxycycline, mice that express the EGFR L858R allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas. In contrast, mice expressing EGFR Δ L747–S752 develop multifocal tumors embedded in normal lung parenchyma with a longer latency. With mice carrying either EGFR allele, withdrawal of doxycycline (to reduce expression of the transgene) or treatment with erlotinib (to inhibit kinase activity) causes rapid tumor regression, as assessed by magnetic resonance imaging and histopathology, demonstrating that mutant EGFR is required for tumor maintenance. These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/gad.1417406

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Self-citation
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer
Kim, C. F. B., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., Vogel, S., Crowley, D. G., Bronson, R. T., & Jacks, T. (2005) · Cell · doi:10.1016/j.cell.2005.03.032 · Cited by 2,229
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605

Flagged first, then by citations

Show all 50 references

Sorted by citations

Items 201–300 of 476

Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis
Morales, C., Wu, M., Hobor, S., Wainwright, E. N., Martin, M. J., Patel, H., Grey, W., Gronroos, E. C., Howell, S. A., Carvalho, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15615-z · Cited by 43
Structural basis of the effect of activating mutations on the EGF receptor
Galdadas, I., Carlino, L., Ward, R. A., Hughes, S. J., Haider, S. M., & Gervasio, F. L. (2021) · eLife · doi:10.7554/elife.65824 · Cited by 42
The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
Calvayrac, O., Mazières, J., Figarol, S., Marty‐Detraves, C., Raymond‐Letron, I., Bousquet, E., Farella, M., Clermont, E., Milia, J., Rouquette, I., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606646 · Cited by 41
Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer
Murillo, M. M., Rana, S., Spencer‐Dene, B., Nye, E. L., Stamp, G., & Downward, J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.003 · Cited by 41
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
Venugopalan, A., Lee, M.-J., Niu, G., Medina-Echeverz, J., Tomita, Y., Lizak, M. J., Cultraro, C. M., Simpson, R. M., Chen, X., Trepel, J. B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11021 · Cited by 40
Impact of age on epidermal growth factor receptor mutation in lung cancer
Ueno, T., Toyooka, S., Suda, K., Soh, J., Yatabe, Y., Miyoshi, S., Matsuo, K., & Mitsudomi, T. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.006 · Cited by 40
Lung Adenocarcinoma: Lessons in Translation from Bench to Bedside
Sangodkar, J., Katz, S., Melville, H., & Narla, G. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20226 · Cited by 38
TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice
Li, A., Zhang, C., Gao, S., Chen, F., Yang, C., Luo, R., & Xiao, H. (2012) · Oncogene · doi:10.1038/onc.2012.253 · Cited by 38
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib‐treated patients with lung adenocarcinoma
Toyooka, S., Takano, T., Kosaka, T., Hotta, K., Matsuo, K., Ichihara, S., Fujiwara, Y., Soh, J., Otani, H., Kiura, K., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00688.x · Cited by 38
Modeling therapy resistance in genetically engineered mouse cancer models
Rottenberg, S., & Jonkers, J. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.002 · Cited by 38
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations
Okamoto, I., Mitsudomi, T., Nakagawa, K., & Fukuoka, M. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010370698 · Cited by 37
Preclinical studies reveal that LSD 1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations
Macheleidt, I. F., Dalvi, P. S., Lim, S., Meemboor, S., Meder, L., Käsgen, O., Müller, M., Kleemann, K., Wang, L., Nürnberg, P., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12382 · Cited by 37
RBM10 Loss Promotes EGFR -Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
Bao, Y., Zhang, S., Zhang, X., Pan, Y., Yan, Y., Wang, N., Ren, Y., Zuo, J., Zong, W., Wang, Z., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1549 · Cited by 37
Oncogenic context shapes the fitness landscape of tumor suppression
Blair, L. M., Juan, J. M., Sebastian, L., Tran, V. B., Nie, W., Wall, G. D., Gerceker, M., Lai, I. K., Apilado, E. A., Grenot, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42156-y · Cited by 36
Self-citation
IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR
Challa, S., Guo, J.-P., Ding, X., Xu, C., Li, Y., Kim, D., Smith, M. A., Cress, W. D., Coppola, D., Haura, E. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0069 · Cited by 37
EGFR-Driven Lung Adenocarcinomas Co-opt Alveolar Macrophage Metabolism and Function to Support EGFR Signaling and Growth
Kuhlmann-Hogan, A., Cordes, T., Xu, Z. Z., Kuna, R. S., Traina, K. A., Robles-Oteíza, C., Ayeni, D. O., Kwong, E. M., Levy, S., Globig, A.-M., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0434 · Cited by 39
Self-citation
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice
Zerbe, L. K., Dwyer‐Nield, L. D., Fritz, J. M., Redente, E. F., Shroyer, R. J., Conklin, E., Kane, S., Tucker, C., Eckhardt, S. G., Gustafson, D. L., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0644-z · Cited by 36
The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures
Balážová, K., Clevers, H. C., & Dost, A. F. M. (2023) · eLife · doi:10.7554/elife.82998 · Cited by 39
Point mutations of protein kinases and individualised cancer therapy
Davies, M. A., Hennessy, B. T., & Mills, G. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.16.2243 · Cited by 34
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Jacobi, N., Seeboeck, R., Hofmann, E., & Eger, A. (2017) · Cancers · doi:10.3390/cancers9040033 · Cited by 36
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
Santarpía, M., Gil, N., & Rosell, R. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2015.1055252 · Cited by 34
Epiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model
Bauer, A. K., Velmurugan, K., Xiong, K.-N., Alexander, C., Xiong, J., & Brooks, R. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22475 · Cited by 34
Stepwise progression from ground-glass opacity towards invasive adenocarcinoma: Long-term follow-up of radiological findings
Soda, H., Nakamura, Y., Nakatomi, K., Tomonaga, N., Yamaguchi, H., Nakano, H., Nagashima, S., Anami, M., Hayashi, T., Tsukamoto, K., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.09.001 · Cited by 34
In vivo activation of the PI3K–Akt pathway in mouse beta cells by the EGFR mutation L858R protects against diabetes
Hakonen, E. T., Ustinov, J., Eizirik, D. L., Sariola, H. V., Miettinen, P. J., & Otonkoski, T. (2014) · Diabetologia · doi:10.1007/s00125-014-3175-2 · Cited by 35
Cell type specificity of female lung cancer associated with sulfur dioxide from air pollutants in Taiwan: An ecological study
Tseng, C.-Y., Huang, Y., Su, S., Huang, J., Lai, C.-H., Lung, C.-C., Ho, C., & Liaw, Y. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-4 · Cited by 33
Cyclin E Transgenic Mice: Discovery Tools for Lung Cancer Biology, Therapy, and Prevention
Freemantle, S. J., & Dmitrovsky, E. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0297 · Cited by 34
In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma
Ambrogio, C., Barbacid, M., & Santamarı́a, D. (2016) · Oncogene · doi:10.1038/onc.2016.385 · Cited by 28
Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors
Ayeni, D. O., Miller, B., Kuhlmann, A., Ho, P., Robles-Oteíza, C., Gaefele, M., Levy, S., de Miguel, F. J., Perry, C. J., Guan, T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0643-8 · Cited by 32
Self-citation
Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response
Kleczko, E. K., Le, A. T., Hinz, T. K., Nguyen, T. T., Navarro, A., Hu, C., Selman, A. M., Clambey, E. T., Merrick, D. T., Lu, S., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216062 · Cited by 31
Transcriptional Profiling of Non-Small Cell Lung Cancer Cells with Activating EGFR Somatic Mutations
Choi, K. C., Creighton, C. J., Stivers, D. N., Fujimoto, N., & Kurie, J. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001226 · Cited by 32
Recombinase-based conditional and reversible gene regulation via XTR alleles
Robles-Oteíza, C., Taylor, S., Yates, T. J., Cicchini, M., Lauderback, B., Cashman, C. R., Burds, A. A., Winslow, M. M., Jacks, T., & Feldser, D. M. (2015) · Nature Communications · doi:10.1038/ncomms9783 · Cited by 33
Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma
Kim, E. Y., Cho, E. N., Park, H. S., Kim, A., Hong, J. Y., Lim, S., Youn, J. P., Hwang, S. Y., & Chang, Y. S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2049-z · Cited by 31
Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression
Evans, J. V., Suman, S., Goruganthu, M., Tchekneva, E. E., Guan, S., Arasada, R. R., Antonucci, A., Piao, L., Ilgisonis, I. S., Bobko, A. A., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad091 · Cited by 31
Transgelin promotes lung cancer progression via activation of cancer-associated fibroblasts with enhanced IL-6 release
Sun, C., Zhang, K., Ni, C., Wan, J., Duan, X., Lou, X., Yao, X., Li, X., Wang, M., Gu, Z., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00463-5 · Cited by 31
Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer
Ebben, J. D., Lubet, R. A., Gad, E. A., Disis, M. L., & You, M. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22405 · Cited by 30
Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M
Kawabata, S., Mercado-Matos, J., Hollander, M. C., Donahue, D., Wilson, W., Regales, L., Butaney, M., Pao, W. J., Wong, K., Janne, P. A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.039 · Cited by 30
Self-citation
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas
Song, X., Fan, P., Bantikassegn, A., Guha, U., Threadgill, D. W., VARMUS, H. E., & Politi, K. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-13-1625 · Cited by 30
Self-citation
USP24-i-101 targeting of USP24 activates autophagy to inhibit drug resistance acquired during cancer therapy
Young, M.-J., Wang, S., Chen, Y.-C., Liu, C.-Y., Hsu, K., Tang, S.-W., Tseng, Y., Wang, Y., Lin, S., & Hung, J. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01277-7 · Cited by 30
Mouse tumour models to guide drug development and identify resistance mechanisms
Thakur, M. D., Pryer, N., & Singh, M. (2013) · The Journal of Pathology · doi:10.1002/path.4285 · Cited by 30
EGFR L858R Mutation and Polymorphisms of Genes Related to Estrogen Biosynthesis and Metabolism in Never-Smoking Female Lung Adenocarcinoma Patients
Yang, S., Yang, T., Chen, K., Li, Y.-J., Hsu, K.-H., Tsai, C.-R., Chen, C., Hsu, C.-P., Hsia, J., Chuang, C.-Y., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2045 · Cited by 30
Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP‐C promoter
Ohashi, K., Rai, K., Fujiwara, Y., Osawa, M., Hirano, S., Takata, K., Kondo, E., Yoshino, T., Takata, M., Tanimoto, M., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00875.x · Cited by 30
Advances in EGFR as a Predictive Marker in Lung Adenocarcinoma
Khalil, F. K., & Altiok, S. (2015) · Cancer Control · doi:10.1177/107327481502200210 · Cited by 30
Histologic transformation in lung cancer: when one door shuts, another opens
Sato, Y., Saito, G., & Fujimoto, D. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221130503 · Cited by 27
Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas
Gao, Y., Vallentgoed, W., & French, P. J. (2018) · Cancers · doi:10.3390/cancers10120489 · Cited by 26
Retinoblastoma Protein Paralogs and Tumor Suppression
Flores, M., & Goodrich, D. W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.818719 · Cited by 28
RhoB Determines Tumor Aggressiveness in a Murine EGFRL858R-Induced Adenocarcinoma Model and Is a Potential Prognostic Biomarker for Lepidic Lung Cancer
Calvayrac, O., Pradines, A., Raymond‐Letron, I., Rouquette, I., Bousquet, E., Lauwers‐Cancès, V., Filleron, T., Cadranel, J. L., Beau‐Faller, M., Casanova, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0506 · Cited by 27
Micro-CT acquisition and image processing to track and characterize pulmonary nodules in mice
Thin, M. Z., Moore, C., Snoeks, T. J. A., Kalber, T. L., Downward, J., & Behrens, A. (2022) · Nature Protocols · doi:10.1038/s41596-022-00769-5 · Cited by 26
Molecular pathology of non‐small cell carcinoma
Yatabe, Y. (2023) · Histopathology · doi:10.1111/his.15080 · Cited by 30
Drug Efficacy Testing in Mice
Kim, W. Y., & Sharpless, N. E. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2011_160 · Cited by 27
How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?Preprint
VARMUS, H. E., Unni, A. M., & Lockwood, W. W. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030866 · Cited by 22
Self-citation
Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy DevelopmentPreprint
Estape, A. A., Foggetti, G., Starrett, J. H., Nguyen, D. X., & Politi, K. A. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037820 · Cited by 23
Self-citation
Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants
Chung, B. M. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i5.806 · Cited by 25
A role for club cells in smoking-associated lung adenocarcinoma
Behrend, S. J., Giotopoulou, G. A., Σπέλλα, Μ., & Stathopoulos, G. T. (2021) · European Respiratory Review · doi:10.1183/16000617.0122-2021 · Cited by 24
A Mouse Model Repository for Cancer Biomarker Discovery
Kelly‐Spratt, K. S., Kasarda, A. E., Igra, M., & Kemp, C. J. (2008) · Journal of Proteome Research · doi:10.1021/pr800210b · Cited by 25
Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain
de Gunst, M. M., Gallegos-Ruiz, M. I., Giaccone, G., & Rodríguez, J. A. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-56 · Cited by 24
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive
Santarpía, M., Altavilla, G., Salazar, M., Magrí, I., Pettineo, G., Benecchi, S., & Rosell, R. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.27 · Cited by 24
Cancer of the Lung: Non-Small Cell Lung Cancer and Small Cell Lung Cancer
Johnson, D. H., Blot, W. J., Carbone, D. P., González, A., Hallahan, D. E., Massion, P. P., Putnam, J. B., & Sandler, A. B. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50080-4 · Cited by 25
Diagnosis and treatment of bronchioloalveolar carcinoma
Raz, D. J., Kim, J. Y., & Jablons, D. M. (2007) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32816ebc62 · Cited by 25
Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice
Ohashi, K., Takigawa, N., Osawa, M., Ichihara, E., Takeda, H., Kubo, T., Hirano, S., Yoshino, T., Takata, M., Tanimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4205 · Cited by 27
Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis
Vaishnavi, A., Juan, J. M., Jacob, M., Stehn, C. M., Gardner, E. E., Scherzer, M. T., Schuman, S. S., van Veen, J. E., Murphy, B., Hackett, C. S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3214 · Cited by 24
Genetically Modified Mouse Models for Biomarker Discovery and Preclinical Drug Testing
Kucherlapati, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2021 · Cited by 24
Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations
Peipp, M., Schneider‐Merck, T., Dechant, M., Beyer, T. D., van Bueren, J. J. L., Bleeker, W. K., Parren, P. W. H. I., van de Winkel, J. G. J., & Valerius, T. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.4338 · Cited by 24
Lung cancers unrelated to smoking: characterized by single oncogene addiction?
Suda, K., Tomizawa, K., Yatabe, Y., & Mitsudomi, T. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0262-y · Cited by 25
Genetic Interactions of STAT3 and Anticancer Drug Development
Fang, B. (2014) · Cancers · doi:10.3390/cancers6010494 · Cited by 25
Systematic identification of CDC34 that functions to stabilize EGFR and promote lung carcinogenesis
Zhao, X., Wang, G., Wen, Z., Zhou, Y., Hu, Q., Zhang, B., Qu, L.-W., Gao, S., Liu, J., Ma, L., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102689 · Cited by 23
CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF‐β signaling
Taki, T., Shiraki, Y., Enomoto, A., Weng, L., Chen, C., Asai, N., Murakumo, Y., Yokoi, K., Takahashi, M., & Mii, S. (2020) · Cancer Science · doi:10.1111/cas.14673 · Cited by 23
Extensive functional evaluation of exon 20 insertion mutations of EGFR
Hirose, T., Ikegami, M., Endo, M., Matsumoto, Y., Nakashima, Y., Mano, H., & Kohsaka, S. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.023 · Cited by 23
Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression
Yang, S., Park, K., Turkson, J., & Arteaga, C. L. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.09.002 · Cited by 23
Smoking and Lung Cancer: Future Research Directions
Haussmann, H. (2007) · International Journal of Toxicology · doi:10.1080/10915810701490463 · Cited by 24
Integrative Genomic Analyses Identifies GGA2 as a Cooperative Driver of EGFR-Mediated Lung Tumorigenesis
O’Farrell, H., Harbourne, B., Kurlawala, Z., Inoue, Y., Nagelberg, A. L., Martinez, V. D., Lu, D., Oh, M. H., Coe, B. P., Thu, K. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.004 · Cited by 23
Prognostic Factors for Gefitinib-Treated Postoperative Recurrence in Non-Small Cell Lung Cancer
Okami, J., Taniguchi, K., Higashiyama, M., Maeda, J., Oda, K., Orita, N., Koizumi, K., Kodama, K., & Kato, K. (2007) · Oncology · doi:10.1159/000112947 · Cited by 22
DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model
Weng, T.-Y., Yen, M.-C., Huang, C.-T., Hung, J.-J., Chen, Y.-L., Chen, W.-C., Wang, C.-Y., Chang, J.-Y., & Lai, M.-D. (2014) · Gene Therapy · doi:10.1038/gt.2014.67 · Cited by 23
Diacylglycerol kinase η modulates oncogenic properties of lung cancer cells
Nakano, T., Iravani, A., Kim, M., Hozumi, Y., Lohse, M., Reichert, E. C., Crotty, T. M., Stafforini, D. M., & Topham, M. K. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-013-1036-y · Cited by 22
Magnetic resonance imaging and spectroscopy of transgenic models of cancer
Raman, V., Pathak, A. P., Glunde, K., Artemov, D., & Bhujwalla, Z. M. (2007) · NMR in Biomedicine · doi:10.1002/nbm.1136 · Cited by 22
Ligand-independent integrin β1 signaling supports lung adenocarcinoma development
Haake, S. M., Plosa, E. J., Kropski, J. A., Venton, L., Reddy, A., Bock, F. M., Chang, B. T., Luna, A. J., Nabukhotna, K., Xu, Z., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.154098 · Cited by 20
EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
Selenz, C., Compes, A., Nill, M., Borchmann, S., Odenthal, M., Florin, A., Brägelmann, J., Büttner, R., Meder, L., & Ullrich, R. T. (2022) · Cancers · doi:10.3390/cancers14163943 · Cited by 21
Biomarkers and transcriptome profiling of lung cancer
Chen, H., Yu, S., Li, K.-C., & Yang, P. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02154.x · Cited by 21
STAT3 expression in activating EGFR-driven adenocarcinoma of the lung
Takata, S., Takigawa, N., Segawa, Y., Kubo, T., Ohashi, K., Kozuki, T., Teramoto, N., Yamashita, M., Toyooka, S., Tanimoto, M., et al. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2011.05.015 · Cited by 21
Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer
Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21
Adenocarcinoma, a molecular perspective
Stahel, R. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm310 · Cited by 20
Novel insights into the molecular origins and treatment of lung cancer
Webb, J. D., & Simon, M. C. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13588 · Cited by 21
Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung
Kozuki, T., Hisamoto, A., Tabata, M., Takigawa, N., Kiura, K., Segawa, Y., Nakata, M., Mandai, K., Eguchi, K., Ueoka, H., et al. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.04.011 · Cited by 21
Transformation to Small Cell Lung Cancer as an Acquired Resistance Mechanism in EGFR-mutant Lung Adenocarcinoma: A Case Report of Complete Response to Etoposide and Cisplatin
Hwang, K., Jung, J.-W., Oh, S.-J., Park, M.-J., Shon, Y.-J., Choi, K. H., Jeong, E., & Kim, H.-R. (2015) · Tumori Journal · doi:10.5301/tj.5000276 · Cited by 20
Epithelial Growth Factor Receptor–Activated Nuclear Factor κB Signaling and Its Role in Epithelial Growth Factor Receptor–Associated Tumors
Pan, D., & Lin, X. (2013) · The Cancer Journal · doi:10.1097/ppo.0000000000000001 · Cited by 23
EGFR Gene Mutation Study in Cytology Specimens
Ma, E. S. K., Ng, W.-K., & Wong, C. L. P. (2012) · Acta Cytologica · doi:10.1159/000343606 · Cited by 20
Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy
Takahashi, T., Sakai, K., Kenmotsu, H., Yoh, K., Daga, H., Ohira, T., Ueno, T., Aoki, T., Hayashi, H., Yamazaki, K., et al. (2021) · Cancer Science · doi:10.1111/cas.15171 · Cited by 21
Chemotherapeutics-resistance “arms” race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer
Singh, P. K., & Silakari, O. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.08.001 · Cited by 20
An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
Tomoshige, K., Guo, M., Tsuchiya, T., Fukazawa, T., Fink-Baldauf, I. M., Stuart, W. D., Naomoto, Y., Nagayasu, T., & Maeda, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0240-1 · Cited by 20
From mice to men: GEMMs as trial patients for new NSCLC therapies
Hayes, S. A., Hudson, A. L., Clarke, S. J., Molloy, M. P., & Howell, V. M. (2014) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2014.04.002 · Cited by 19
Approach to the Subsolid Nodule
Mase, V. J., & Detterbeck, F. C. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.11.004 · Cited by 19
Stem cells and lung cancer: future therapeutic targets?
Alison, M. R., Brenne, A. C. L., & Islam, S. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903103803 · Cited by 19
Plasma signals of lung tumor promotion for molecular cancer prevention
Pandya, T., Zagorulya, M., Leung, M. M., Augustine, M., Liu, L., Leppä, A., Baruchel, U., Ng, S. W., Klockner, T., Mugabo, M., et al. (2026) · Cell · doi:10.1016/j.cell.2026.05.005 · Cited by 22
The Interplay between Dysregulated Metabolism and Epigenetics in Cancer
Bassal, M. A. (2023) · Biomolecules · doi:10.3390/biom13060944 · Cited by 19
Epithelial NF-κB signaling promotes EGFR-driven lung carcinogenesis via macrophage recruitment
Saxon, J. A., Sherrill, T. P., Polosukhin, V. V., Sai, J., Zaynagetdinov, R., McLoed, A. G., Gulleman, P. M., Barham, W. J., Cheng, D., Hunt, R. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1168549 · Cited by 18
Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression
Götz, R. (2008) · Cancer Cell International · doi:10.1186/1475-2867-8-7 · Cited by 19
Practical Use of Advanced Mouse Models for Lung Cancer
Safari, R., & Meuwissen, R. L. J. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2297-0_5 · Cited by 17
Gefitinib-Sensitive EGFR Lacking Residues 746–750 Exhibits Hypophosphorylation at Tyrosine Residue 1045, Hypoubiquitination, And Impaired Endocytosis
Furukawa, M., Nagatomo, I., Kumagai, T., Yamadori, T., Takahashi, R., Yoshimura, M., Yoneda, T., Takeda, Y., Goya, S., Matsuoka, H., et al. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0573 · Cited by 18
The role of cancer stem cells in neoplasia of the lung: past, present and future
Yagui‐Beltrán, A., He, B., & Jablons, D. M. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0278-6 · Cited by 17
Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
Kim, T., Han, S., & Bang, Y. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.6.821 · Cited by 16
Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment
Jang, H.-J., Lee, H., Yu, W., Ramineni, M., Truong, C., Ramos, D., Splawn, T. G., Choi, J. M., Jung, S. Y., Lee, J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3506 · Cited by 17

Authors: Politi, K., Zakowski, M. F., Fan, P.-D., Schonfeld, E. A., Pao, W., & Varmus, H. E.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Politi, Katerina
Zakowski, Maureen F.
Fan, Pang-Dian
Schonfeld, Emily A.
Pao, William
Varmus, Harold E.
Venue: Genes & Development
Publisher: Cold Spring Harbor Laboratory
Published: 2006-05-16
Volume: 20
Issue: 11
Pages: 1496-1510
ISSN: 0890-9369 (ISSN-L)
1549-5477
DOI: 10.1101/gad.1417406
OpenAlex: W2126181231
Cited by: 478
References: 50
Citations by year: 2026: 10 · 2025: 14 · 2024: 18 · 2023: 23 · 2022: 15 · 2021: 17 · 2020: 15 · 2019: 9 · 2018: 24 · 2017: 11 · 2016: 23 · 2015: 38 · 2014: 25 · 2013: 19 · 2012: 27
Type: posted content
Language: en
Open access: bronze
doi.org
Locations: Genes & Development (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
Funders: Memorial Sloan-Kettering Cancer Center
Dana-Farber Cancer Institute
University of Cincinnati
National Institutes of Health (R24 CA83084)
Genentech
National Cancer Institute (K08CA097980, R24CA083084)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: lung adenocarcinoma, epidermal growth factor receptor, EGFR mutation, exon 19 deletion, L858R mutation, tyrosine kinase inhibitors, erlotinib, gefitinib, transgenic mouse model, alveolar type II cells, tumor regression, tumor maintenance, doxycycline-inducible expression, bronchioloalveolar carcinoma
MeSH terms: Adenocarcinoma, Animals, Base Sequence, Humans, Lung Neoplasms, Magnetic Resonance Imaging, Phosphorylation, Protein-Tyrosine Kinases, Down-Regulation, DNA Primers, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lung adenocarcinomas induced in mice by mutant EGF receptors foundin human lung cancers respondto a tyrosine kinase inhibitor orto down-regulation of the receptors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks